Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic

M. Safarikova, J. Stekrova, E. Honsova, V. Horinova, V. Tesar, J. Reiterova,

. 2018 ; 19 (1) : 147. [pub] 20180820

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19028262

BACKGROUND: Mutations in INF2 are frequently responsible for focal segmental glomerulosclerosis (FSGS), which is a common cause of end stage renal disease (ESRD); additionally, they are also connected with Charcot-Marie-Tooth neuropathy. INF2 encodes for inverted formin 2. This protein participates in regulation of the dynamics of the actin cytoskeleton, involving not only the polymerisation, but also the depolymerisation of filaments. The present study is the first mutational analysis of INF2 done in the Czech Republic. METHODS: Mutational analysis of INF2 was performed on 109 patients (mean age at onset 41.44 ± 18.91 years) with FSGS or minimal change disease (MCD); and also in 6 patients without renal biopsy who had already developed chronic kidney disease (CKD)/ESRD at the time of diagnosis. We used high resolution melting method (HRM), with subsequent Sanger sequencing, in suspect samples from HRM analysis. The HRM method is an effective method for the screening of large cohorts of patients. RESULTS: Two pathogenic mutations (p.Arg214His and p.Arg218Gln) were detected in INF2. The first (p.Arg214His) was identified in the FSGS patient with a positive family history. The second mutation (p.Arg218Gln) was found in two brothers with ESRD of unknown etiology. The most frequent sequence change was the substitution p.P35P, the incidence of which corresponded with the frequencies available in the ExAC Browser and gnomAD Browser databases. This analysis also detected different exonic and intronic changes that probably did not influence the phenotype of the included patients. CONCLUSIONS: The INF2 mutational screening is useful in familial FSGS cases as well as in patients with an unknown cause for their ESRD, but with a positive family history. INF2 seems to be not only the cause of FSGS, but also of ESRD of unknown etiology. Our study has confirmed that the HRM analysis is a very useful method for the identification of single nucleotide substitutions.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028262
003      
CZ-PrNML
005      
20190822085310.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12881-018-0667-9 $2 doi
035    __
$a (PubMed)30126379
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Safarikova, Marketa $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. marketasafarikova@seznam.cz. Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. marketasafarikova@seznam.cz.
245    10
$a Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic / $c M. Safarikova, J. Stekrova, E. Honsova, V. Horinova, V. Tesar, J. Reiterova,
520    9_
$a BACKGROUND: Mutations in INF2 are frequently responsible for focal segmental glomerulosclerosis (FSGS), which is a common cause of end stage renal disease (ESRD); additionally, they are also connected with Charcot-Marie-Tooth neuropathy. INF2 encodes for inverted formin 2. This protein participates in regulation of the dynamics of the actin cytoskeleton, involving not only the polymerisation, but also the depolymerisation of filaments. The present study is the first mutational analysis of INF2 done in the Czech Republic. METHODS: Mutational analysis of INF2 was performed on 109 patients (mean age at onset 41.44 ± 18.91 years) with FSGS or minimal change disease (MCD); and also in 6 patients without renal biopsy who had already developed chronic kidney disease (CKD)/ESRD at the time of diagnosis. We used high resolution melting method (HRM), with subsequent Sanger sequencing, in suspect samples from HRM analysis. The HRM method is an effective method for the screening of large cohorts of patients. RESULTS: Two pathogenic mutations (p.Arg214His and p.Arg218Gln) were detected in INF2. The first (p.Arg214His) was identified in the FSGS patient with a positive family history. The second mutation (p.Arg218Gln) was found in two brothers with ESRD of unknown etiology. The most frequent sequence change was the substitution p.P35P, the incidence of which corresponded with the frequencies available in the ExAC Browser and gnomAD Browser databases. This analysis also detected different exonic and intronic changes that probably did not influence the phenotype of the included patients. CONCLUSIONS: The INF2 mutational screening is useful in familial FSGS cases as well as in patients with an unknown cause for their ESRD, but with a positive family history. INF2 seems to be not only the cause of FSGS, but also of ESRD of unknown etiology. Our study has confirmed that the HRM analysis is a very useful method for the identification of single nucleotide substitutions.
650    _2
$a dospělí $7 D000328
650    _2
$a Charcotova-Marieova-Toothova nemoc $x genetika $x metabolismus $7 D002607
650    _2
$a kohortové studie $7 D015331
650    _2
$a mutační analýza DNA $x metody $7 D004252
650    _2
$a exony $x genetika $7 D005091
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fokálně segmentální glomeruloskleróza $x genetika $x metabolismus $7 D005923
650    _2
$a lidé $7 D006801
650    _2
$a introny $x genetika $7 D007438
650    _2
$a chronické selhání ledvin $x genetika $x metabolismus $7 D007676
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikrofilamentové proteiny $x genetika $x metabolismus $7 D008840
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a fenotyp $7 D010641
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stekrova, Jitka $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Honsova, Eva $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Horinova, Vera $u Reprofit International, Brno, Czech Republic.
700    1_
$a Tesar, Vladimir $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Reiterova, Jana $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
773    0_
$w MED00008188 $t BMC medical genetics $x 1471-2350 $g Roč. 19, č. 1 (2018), s. 147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30126379 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822085549 $b ABA008
999    __
$a ok $b bmc $g 1433411 $s 1066722
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 1 $d 147 $e 20180820 $i 1471-2350 $m Bmc medical genetics $n BMC Med Genet $x MED00008188
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Logged in users only

Archiving options